Swiss pharma giant Roche said on Monday it is buying US firm GenMark Diagnostics for $1.8 billion (€1.5bn).

GenMark, based in California, makes molecular tests which can establish the presence of several different pathogens from just one sample, it said.

GenMark, based in California, makes molecular tests which can establish the presence of several different pathogens from just one sample

Roche said it is offering $24.05 a share for GenMark, a premium of some 43 per cent to its last quoted share price on February 10.

“Acquiring GenMark Diagnostics will increase our portfolio of molecular diagnostic (tests),” the company said in a statement.

The deal, subject to regulatory approval, should be concluded in the second quarter, it added.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.